RNS Number : 4694Z
EKF Diagnostics Holdings PLC
16 March 2012
 



EKF Diagnostics Holdings plc

("EKF" or "the Company")

 

Trading Update & Notice of Final Results

 

EKF Diagnostics Holdings plc (AIM: EKF), a worldwide manufacturer of point of care in-vitro diagnostic devices, will announce its final results for the year ended 31 December 2011 on Wednesday, 21 March 2012.

 

As announced on 19 January 2012, trading in the second half of 2011 was strong with unaudited revenues for the year ended 31 December 2011 of approximately £21.6m, and the Board now believes that adjusted EBITDA will be materially ahead of already revised market expectations.

 

The management team will be hosting analyst and media briefings on the day. For more information please contact Walbrook PR Ltd.

 

Enquiries:

EKF Diagnostics Holdings plc     

Tel: 029 2071 0570

David Evans, Executive Chairman

Mob: 07740 084 452

Julian Baines, CEO

Mob: 07788 420 859



Collins Stewart Europe Limited

Tel: 020 7523 8000

Jamie Adams / Mark Dickenson


 

Walbrook PR Limited

Tel: 020 7933 8780

Fiona Henson

Mob: 07886 335 992 or fiona.henson@walbrookpr.com

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

 

 

 

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).

 

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

 

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2. 

 

For more information please visit the website: www.ekfdiagnostics.co.uk

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCJAMMTMBBBTJT
admin Trading Update & Notice of Final Results 19960627 A Fri, 03/16/2012 - 07:00 Company Announcement - General EKF